G&A at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's G&A?
- Summit Therapeutics (SMMT) reported G&A of $62.59M in Q1 2026.
- How has Summit Therapeutics's G&A changed year-over-year?
- Summit Therapeutics's G&A increased by 301.6% year-over-year, from $15.59M to $62.59M.
- What is the long-term trend for Summit Therapeutics's G&A?
- Over 4 years (2021 to 2025), Summit Therapeutics's G&A has grown at a 120.4% compound annual growth rate (CAGR), from $23.61M to $556.75M.
- What does G&A mean?
- The overhead costs of running the company's daily business operations.
- How do you interpret G&A?
- A decrease relative to revenue indicates improved operational efficiency, while an increase may suggest rising administrative bloat or scaling costs.
- How does G&A compare across companies?
- Benchmark against peer SG&A ratios to determine if administrative costs are disproportionate to the company's size.